Arterial Stiffness May Predict Subsequent Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer Patients
Authors:
Open Access
- 8 March 2024
- journal article
- research article
- Published by Springer Nature in Cardiovascular Toxicology
- Vol. 24 (4) , 375-384
Abstract
Cancer therapy-related cardiac dysfunction (CTRCD) is still a serious problem. Existing risk scores are insufficient for risk classification, especially in low and medium-risk patients. This study aims to evaluate if arterial stiffness (AS) measurement, which is associated with most of the known risk factors, can be a useful parameter for predicting subsequent CTRCD in patients with breast cancer (BC). Patients with BC were included in the study. All patients’ AS parameters such as pulse wave velocity (PWV), augmentation index (AIx), augmentation pressure (AP), and echocardiographic parameters were obtained before treatment. During treatment, echocardiographic follow-up with routine parameters and left ventricle global longitudinal strain (LVGLS) were measured. Patients were evaluated on whether CTRCD occurred or not. A total of 67 patients were analyzed. The mean age of the study population was 54.9 ± 11 years. Baseline characteristics were similar except for age. No CTRCD diagnosis was obtained according to left ventricle ejection fraction (LVEF) reduction, but 18 patients (26.8%) developed CTRCD regarding the decline in LVGLS. Left ventricle hypertrophy and diastolic dysfunction were more frequent in patients with CTRCD (p = 0.016 and p = 0.015, respectively). PWV, AIx, and AP as AS parameters were significantly higher in patients with CTRCD, but Alx@75 were not (p = 0.005, p = 0.034, p = 0.008, p = 0.077, respectively). A positive correlation between PWV and a decreased percent in LVGS (R = 0.607, p < 0.001) was observed. ROC curve analyses revealed an AUC of 0.747 (p = 0.02, 95% CI 0.632–0.832) for PWV. A PWV value of 9.2 m/s predicted CTRCD with 94% sensitivity and 73% specificity. AS measurement may be useful for predicting CTRCD in patients with low to medium-risk BC. Graphical AbstractKeywords
Funding Information
- Karadeniz Technical University
This publication has 27 references indexed in Scilit:
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)European Heart Journal, 2022
- Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyEuropean Journal of Heart Failure, 2020
- Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendationsAnnals of Oncology, 2020
- The Need for Cardiovascular Risk Factor Prevention in Cardio-OncologyJACC: Heart Failure, 2019
- Ventricular-arterial coupling in centenarians without cardiovascular diseasesAging Clinical and Experimental Research, 2017
- Proximal Aortic Distensibility Is an Independent Predictor of All-Cause Mortality and Incident CV EventsJACC, 2014
- Aortic Stiffness, Blood Pressure Progression, and Incident HypertensionJAMA, 2012
- Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort StudyJNCI: Journal of the National Cancer Institute, 2012
- Prediction of Cardiovascular Events and All-Cause Mortality With Arterial StiffnessJACC, 2010
- Expert consensus document on arterial stiffness: methodological issues and clinical applicationsEuropean Heart Journal, 2006